Annovis Bio Balance Sheet Health
Financial Health criteria checks 1/6
Annovis Bio has a total shareholder equity of $-3.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $7.8M and $11.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$3.14m |
| Equity | -US$3.35m |
| Total liabilities | US$11.17m |
| Total assets | US$7.81m |
Recent financial health updates
Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely
Sep 08
We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth
Jan 28We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely
Sep 15Annovis Bio (NYSE:ANVS) Is In A Good Position To Deliver On Growth Plans
May 14We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth
Feb 10Here's Why We're Not Too Worried About Annovis Bio's (NYSEMKT:ANVS) Cash Burn Situation
Apr 16Recent updates
Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question
May 02Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's Prospects
Feb 12Annovis And Alzheimer's Disease: The Best-Laid Plans
Jan 30Annovis Bio: Buntanetap Likely To Disappoint In The Upcoming AD And PD Clinical Trials
Jan 20Annovis: Due Diligence Prior To Parkinson's And Alzheimer's Readouts
Oct 16Annovis Bio (NYSE:ANVS) Will Have To Spend Its Cash Wisely
Sep 08Annovis Bio: End Of 2023 Parkinson's Data Could Shift Momentum
Jun 28Annovis wins EU nod to expand late-stage trial for Parkinson's candidate
Feb 08We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth
Jan 28Annovis gains amid ‘strong’ enrollment in late-stage trial Parkinson's drug
Jan 25Annovis: Late-Stage Parkinson's Disease Trial Advancement Makes It Worth A Look
Oct 06We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely
Sep 15Annovis Bio announces publication of three U.S. patents covering lead asset
Sep 13Annovis Bio gains as dosing begins in late-stage trial for Parkinson’s candidate
Aug 24Annovis Bio wins FDA nod to begin late-stage study for Parkinson's candidate
Jul 07Annovis Bio (NYSE:ANVS) Is In A Good Position To Deliver On Growth Plans
May 14We Think Annovis Bio (NYSE:ANVS) Can Afford To Drive Business Growth
Feb 10Here's Why We're Not Too Worried About Annovis Bio's (NYSEMKT:ANVS) Cash Burn Situation
Apr 16Do Institutions Own Annovis Bio, Inc. (NYSEMKT:ANVS) Shares?
Feb 23We Think Annovis Bio (NYSEMKT:ANVS) Can Afford To Drive Business Growth
Jan 01
Financial Position Analysis
Short Term Liabilities: ANVS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ANVS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ANVS is debt free.
Reducing Debt: ANVS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ANVS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ANVS has less than a year of cash runway if free cash flow continues to reduce at historical rates of 60.5% each year